Navigation Links
Astra Tech Acquires Innovative Dental Digital Technology Company
Date:9/27/2007

leted tooth. The end result is more attractive and extremely reliable. For the patient it means fewer trips to the dentist since the abutment always fits perfectly without the dentist having to make adjustments. Atlantis' method makes it possible to fabricate individual abutments for most of the major implant systems on the market. For dental laboratories, this makes their work more efficient and profitable.

Atlantis Components Inc. is based in Cambridge, Massachusetts and has 100 employees. The company has had very positive growth in recent years and now has a market-leading position in its segment.

(1) CAD=Computer-Aided Design CAM=Computer-Aided Manufacturing

"Astra Tech with its focus on research and its global sales organization is the perfect owner for Atlantis as it offers the ideal environment within which to further develop Atlantis' unique technology as well as grow the business," says Bob Stockard, CEO, Atlantis.

Operations will be integrated with Astra Tech's North American subsidiary headquartered in Waltham, MA. The North American market represents approximately one third of the world market and is Astra Tech's most important one. It is currently one of the fastest growing markets for the Astra Tech Group.

"The two companies complement each other perfectly. Through the acquisition of Atlantis, we can offer all dentists working with implants an optimal solution, in terms of both esthetics and function," says Scott Root, President and CEO, Astra Tech Inc., North America.

"We will develop a Center of Excellence in the US for esthetics, based on Atlantis' unique know-how and technology in order to offer advanced digital dentistry solutions," says Peter Selley.

In 2008, Astra Tech will begin producing Atlantis' CAD/CAM abutments for the European market at its headquarters in Molndal, Sweden. The launch and sales in Europe will be handled by Astra Tech's existing sales organization.

As recently as June of this
'/>"/>

SOURCE Astra Tech
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Ayurvastra Initiative Launched
2. Astra Zenecas Seroquel Gets FDA Approval For Schizophrenia
3. Astrazenecas Investigational Cancer Therapies Revealed at ASCO
4. Ossur Acquires the U.S. Orthopaedics Company
5. Stem of Hope: Stem Cell Research Acquires a Brittle Star As A model
6. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
7. Premier Army Hospital Acquires PET-CT Scanner
8. Wockhardt acquires Protinex, Farex brands from Netherland Co
9. Indoco Remedies Acquires La Nova Chem
10. Ranbaxy Acquires Glaxosmithklines Generic Unit in Spain
11. AIIMS Acquires Four-Armed Robot to Assist in Surgeries
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Is There Really Such a Thing as Hope in a Jar? 2Health News:Is There Really Such a Thing as Hope in a Jar? 3Health News:Is There Really Such a Thing as Hope in a Jar? 4Health News:Is There Really Such a Thing as Hope in a Jar? 5Health News:CDC Reports Drop in Adult Smoking, But Death Toll and Health Costs Are Still Growing; Congress, States Should Implement Proven Solutions 2Health News:CDC Reports Drop in Adult Smoking, But Death Toll and Health Costs Are Still Growing; Congress, States Should Implement Proven Solutions 3Health News:CDC Reports Drop in Adult Smoking, But Death Toll and Health Costs Are Still Growing; Congress, States Should Implement Proven Solutions 4Health News:Elizabeth Edwards Reschedules Metro Detroit Appearance 2Health News:HIV Vaccine Failure Still Brings Insights 2Health News:Misonix Reports First Quarter Fiscal Year 2009 Financial Results 2Health News:Misonix Reports First Quarter Fiscal Year 2009 Financial Results 3Health News:Misonix Reports First Quarter Fiscal Year 2009 Financial Results 4Health News:Misonix Reports First Quarter Fiscal Year 2009 Financial Results 5Health News:Misonix Reports First Quarter Fiscal Year 2009 Financial Results 6Health News:Misonix Reports First Quarter Fiscal Year 2009 Financial Results 7Health News:Misonix Reports First Quarter Fiscal Year 2009 Financial Results 8Health News:Misonix Reports First Quarter Fiscal Year 2009 Financial Results 9Health News:Relationship between prostate information and lower urinary-tract symptoms evident 2
Breaking Medicine Technology:Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 2Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 3Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 4Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 5Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 6Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 7GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4IMAGINE Software Unveils Advanced IMAGINEradiology 28TM 29 Features 47841 1IMAGINE Software Unveils Advanced IMAGINEradiology 28TM 29 Features 47841 2Americas Future Now Straw Poll 3A Progressives See Health Care Reform With Public Option As Top Priority 47838 1Americas Future Now Straw Poll 3A Progressives See Health Care Reform With Public Option As Top Priority 47838 2Medical Insurance Automotive and Safety Groups Call on Congress to Make This the 22Last Deadly Summer for Teens 22 by Swiftly Passing Federal Teen 47835 1Medical Insurance Automotive and Safety Groups Call on Congress to Make This the 22Last Deadly Summer for Teens 22 by Swiftly Passing Federal Teen 47835 2Medical Insurance Automotive and Safety Groups Call on Congress to Make This the 22Last Deadly Summer for Teens 22 by Swiftly Passing Federal Teen 47835 3
Other Medicine Technology:Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 2Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 3Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 4Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 5Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 6Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 7Senesco's Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences 2Senesco's Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences 3